Key Highlights

  • Galleri test Revenue grew 14% year over year to USD 37.3 million in the third quarter of 2026, while total revenue rose 4% to USD 37.5 million.
  • Galleri test Volume increased about 24% to more than 56,000 tests, and year-to-date volume rose about 36% to more than 174,000 tests, with nine-month Galleri revenue up 24% to USD 119.7 million.
  • GRAIL (NASDAQ:GRAL) posted a net loss of USD 103.6 million, up USD 14.6 million or 16% from a year earlier, with adjusted EBITDA of negative USD 92.6 million.
  • Cash, cash equivalents and short-term marketable securities totaled USD 788.7 million at September 30, 2026, and the company anticipates an FDA decision on Galleri by early Q1 2027.

Galleri Volume Growth Outpaces Revenue in the Third Quarter

GRAIL (NASDAQ:GRAL) reported third-quarter 2026 results on November 4, 2026, with total revenue of USD 37.5 million, up USD 1.3 million or 4%. Galleri test revenue was USD 37.3 million, up 14%, and test volume grew about 24% to more than 56,000, a gap that fits the promotional pricing initiatives management mentioned, although the release does not quantify them. The company develops a blood-based multi-cancer early detection test that looks for DNA shed by cancer cells. Over nine months, Galleri volume rose about 36% to more than 174,000 tests and revenue climbed 24% to USD 119.7 million. The release gives no revenue guidance and no per-share loss figure.

Losses Widen as the FDA Panel Vote Becomes the Central Catalyst

Net loss was USD 103.6 million, an increase of 16%. Gross loss widened to USD 18.1 million from a loss roughly USD 4.4 million smaller, a 32% increase, and non-GAAP adjusted Gross Profit fell 20% to USD 15.9 million. Adjusted EBITDA loss was USD 92.6 million, up 29%. The regulatory story is the offset: in September, the FDA's Molecular and Clinical Genetics Panel of the Medical Device Advisory Committee voted favorably on approval of Galleri. The company anticipates an FDA decision by early Q1 2027. The Galleri test has not been cleared or approved by the FDA, so the advisory vote is not an approval and the agency is not bound by it.

Trial Data, Cash Draw and What to Watch Into 2027

GRAIL cited results from the NHS-Galleri trial and the PATHFINDER 2 study, covering approximately 175,000 participants, with 4 to 6.5 times more cancers detected and a reduction of more than 20% in Stage IV diagnoses of 12 prespecified aggressive cancers in the NHS-Galleri trial. On the balance sheet, cash and short-term securities of USD 788.7 million compare with about USD 904.4 million at December 31, 2025 (calculated from the balance sheet), a decline of roughly USD 115.7 million over nine months. The company held USD 29.0 million of cash itself and USD 759.7 million of short-term marketable securities. Reimbursement and broader access remain open questions the release does not resolve.

Where Things Stand

It can only if the FDA decision and reimbursement follow, and neither is assured yet. GRAIL (NASDAQ:GRAL) grew Galleri revenue 14% and volume about 24%, and the advisory panel vote was favorable, but the quarter still produced a USD 103.6 million net loss and a gross loss. The Balance Sheet has USD 788.7 million of cash and short-term securities to fund the path. Next markers are the FDA decision anticipated by early Q1 2027, fourth-quarter test volumes, and any reimbursement progress the company reports.